Agenus Inc AGEN
Agenus Inc (Nasdaq: AGEN) is an oncology drug developer. Its lead program, Botensilimab (BOT) plus balstilimab (BAL), is in Phase 2 for Refractory MSS/pMMR metastatic colorectal cancer without active liver metastases (also neoadjuvant MSS colon cancer). Its next catalyst on record is NEST and UNICORN (BOT/BAL neoadjuvant): Further study details anticipated to be published (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: NEST and UNICORN (BOT/BAL neoadjuvant) — Further study details anticipated to be published (H2 2026). 5 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BOT/BAL | Refractory MSS metastatic colorectal cancer (randomized Phase 2 and Phase 1b completed; accelerated approval filing planned) | antibody | Phase 2 |
| BOT/BAL (ROBBIN; NEST and UNICORN investigator-sponsored Phase 2 studies) | High-risk Stage II/III MSS colon cancer, neoadjuvant | antibody | Phase 2 |
| AGEN1777 (TIGIT bispecific) | Solid tumors (rights returned by BMS Jan 2025; postponed) | antibody | Phase 2 |
| BOT/BAL | Ovarian cancer, sarcoma, NSCLC, HCC, melanoma (Phase 1b C-800-01) | antibody | Phase 1 |
| AGEN2373 (CD137 agonist) | Advanced solid tumors | antibody | Phase 1 |
| AGEN1423 (CD73/TGF-beta TRAP) | — | antibody | Pre-clinical |
| AGEN1571 (ILT2) | — | antibody | Pre-clinical |
Recent results and decisions
- Jul 13, 2026discontinued Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 trial in late-line metastatic MSS colorectal cancer to focus on neoadjuvant colon cancer.
To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer
Filing - Jul 13, 2026positive Neoadjuvant BOT+BAL in NEST and UNICORN Phase 2 studies: pathologic response ~60-70%, major pathologic response ~35-40%, pCR ~30%; all treated patients disease free at 9-18 months follow-up.
BOT+BAL has produced deep, durable responses, including pathologic response (PR) in approximately 60-70% of patients, major pathologic response (MPR) in approximately 35-40% of patients and pathologic complete response (pCR) in approximately 30% of patients.
Filing - Mar 16, 2026started BATTMAN Phase 3 registrational trial of BOT+BAL in refractory MSS metastatic colorectal cancer is underway (approx. 830 patients planned).
BATTMAN Phase 3 registrational trial underway: First global next-generation CTLA-4/PD-1 combination registrational trial in refractory MSS mCRC
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.